A during prescribed FDA Thank more that Alan. to XXXX. NERLYNX you, be thousands to then, forward NERLYNX U.S. presentation in have our the I making to patients in of Since market my continuing provide reaching will physicians. We reminder been look NERLYNX. approval has patients and forward-looking more of statements. July been since
prior The six pharmacies NERLYNX pharmacies the specialty the insurance approval a then of send and network provide arrange with to our patients. recall, directly investigations, to may patient their specialty home. NERLYNX obtain conduct benefit from authorization company you to As
patients sent the be does to the office, health have channel This dispensing not obtain need to pharmacy. from a separate integrated to for facilitate directly also where the also certain We their prescription systems specialty and helps NERLYNX to distribution VA. ability in-office specialty physician's the
and XXXX networks. for channel by establishing throughout patients, the XXXX To better into physician partnerships expanded allow access distribution we with
this result, have continued specialty a and dispensed As physician through an patients practices to see distribution increase network. NERLYNX hospitals we in being in
sales the second now continued financial Maximo sold to grow the channel Later during the as approximately in results, quarter. the review in you second but provide and quarter, current as much total the bottles full XX% results. represented will will I certain weeks In with of call, sales in this
X, net Slide quarterly approval. since FDA NERLYNX see On sales you of
in sales by increase higher The $XX.X in XX% our mentioned, the the net an million quarter, second Alan the increase next revenue driven shown quarter. volumes As was product prior bottle the from revenue slide. was
We quarter, I point. Last experienced key an that our increase reported sales in of volume several in at the higher had some factors. second due than force XX quarter were the a rate open we to in XX territories where vacancy average
of am positions happy as those are filed. to opened previously report today, all that I of
trained the out are All hires calling has field. of increased actively new targeted which these on field the in recently our in presence physicians now
fellow and patients. increase our nurse to management We efforts have physician effect also educator on added in our educating practices to team for side nurses nurses
by dispensing attributed in Secondly, of specialty in-office setting NERLYNX in is in the is the increase serviced distribution dispensing the volume channel. growth to which
have we partnerships this mentioned, to see and for allow segment. physician in-office As established continue networks in growth to quarter-over-quarter dispensing with
quarter specialty Slide bottles X distribution. In XXXX. This X.X% NERLYNX, first sold of and of we NERLYNX of channels; XXXX, the pharmacy of shows of bottles second all an quarterly represents specialty the sold. the volume over quarter increase X,XXX
continued and NERLYNX have the marketing and adjuvant and the of rationale with recurrence risk increase patients educate for on in sales to Our treatment to efforts extended organizations setting. physicians the disease
importance to efforts management. patients of addition, the educate increased and we In nurses physicians, anti-diarrheal about
why a side NERLYNX mentioned in patient first As the the to The month. the reason early the discontinues occur effects. in primary due discontinuations more frequently past, is
NERLYNX, show also of anti-diarrheal to patients believe prescribe data were fill CONTROL at anti-diarrheal all, an we due most While which medications physicians was medication not our lack physicians using to anti-diarrheal not awareness from may trial drugs. continues that of the prescription. research prescribing some the any There prophylactic the anti-diarrheal prophylaxis some our with
recall, the budesonide, or for loperamide, other to obtain may supportive our medications. colestipol, help launched you As patients eliminate care financial voucher to anti-diarrheal we barrier
reeducate about and In a This tolerability. permanently concerted reductions have dose discontinue. patients and on NERLYNX this, increase dose stay we addition to to not allows effort to holds doctors to
practicing exchanges. options these in highlighted continue of be oncologists to All peer-to-peer by
help our ones and team, side management. in the specifically are effect practice Moreover, we often the nurses, which have patients fellow own nurse about educator also who practices dedicated who educate educate
an more the tolerability. team As mentioned effort to earlier, nurse we NERLYNX improve have educators recently added clinical in to
in we and has and X, patients has XX payer it of sign you these NERLYNX most good continued patients a XX coverage. less, in process throughout a days that less, This Slide NERLYNX smooth days reimbursement the receive believe or On been consistent which in of receive time market. continuing is the or XX% see been
on who such insurance contribute the needs company right-hand There of more not as prescribed shown been metastatic, a for market to continue we number the or where These which patients of information. HERX-mutated HERX-amplified, NERLYNX the longer have slide. side do small cancer, off-label promote, is use, field or to times situations
on prescribers on Slide to Now X.
drug. have make met sales increasing physicians them continue not physician sales reaching not in in quarter. is the This there target progress Since are force or reflected conferences We restricting the used the here. reps, we who with, other to which to physicians represents have have who through opportunities our in prescribed second numbers medical audience, to online, to reach more our physicians XX% access
reduce focused requires with to a providing on numerous on we need which discussion side prescribing effects. regarding and A education are also efficacy on physicians highly This managing discussion NERLYNX the establishing the doing. involves recurrence, interactions,
metric also reach, this earnings with focus presentations, the more frequency the transparency quality future base. that Therefore, our of at we gives and the look of depth when we In one will be prescriber reaching likely interactions. we replacing into on
are to world. committed available making across patients to the we NERLYNX mentioned, Alan As
expertise have that regulatory and have formed throughout with We who world great in region. the companies commercial partnerships
in X. Canada look are and approval this in year see Slide We more as to the pleased forward you with recent
Specifically in With NERLYNX to on and EU, we Europe, planning United the Germany, Pierre approval as with are in Pierre partnering of year. Fabre Kingdom Alan the this our regulatory Austria is in mentioned, currently the Fabre. quarter fourth launching
able To to to grow sales summarize, we sequentially QX. were from QX
our with patients. payers continued are progress physicians, focused We and on intensely improving
prescribers patients and and on more their resources important medication. reach to continue stay help to dedicate We receive
NERLYNX. all appropriate ensuring access to patients We have are committed to
now will review Maximo financial our of results. a the I over for turn call to
